A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

Condition: Asthma
Intervention: Biological: Mepolizumab
Sponsor: GlaxoSmithKline
Not yet recruiting – verified May 2014